Journal of Chemistry
15
Figure 4: 13C NMR (100 MHz, CDCl3) spectrum of 2-
[10] A. M. Farghaly, N. S. Habib, M. A. Khalil, O. A. El-Sayed, and
A. E. Bistawroos, “Synthesis of novel 2-substituted quinoline
derivatives: antimicrobial, inotropic, and chronotropic ac-
tivities,” Archiv der Pharmazie, vol. 323, no. 4, pp. 247–251,
1990.
[11] B. Swamy, Y. Praveen, N. Pramod, B. Shivkumar,
H. Shivkumar, and R. Rao, “Synthesis, characterization and
anti-inflammatory activity of 3-formyl 2-hydroxy quinoline
thiosemicarbazides,” Journal of Pharmacy Research, vol. 5,
no. 5, pp. 2735–2737, 2012.
[12] N. Khalifa, M. Al-Omar, A. El-Galil, and M. El-Reheem,
“Anti-inflammatory and analgesic activities of some novel
carboxamides derived from 2-phenyl quinoline candidates,”
Biomedical Research, vol. 28, no. 2, pp. 869–874, 2017.
[13] S. Gupta and A. Mishra, “Synthesis, characterization &
screening for anti-inflammatory & analgesic activity of
quinoline derivatives bearing azetidinone scaffolds,” Anti-
Inflammatory & Anti-allergy Agents in Medicinal Chemistry,
vol. 15, no. 1, 2016.
[14] X. Nqoro, N. Tobeka, and B. Aderibigbe, “Quinoline-based
hybrid compounds with antimalarial activity,” Molecules,
vol. 22, no. 12, p. 2268, 2017.
[15] S. Nara and A. Garlapati, “Design, Synthesis and molecular
docking study of hybrids of quinazolin-4(3H)-one as anti-
cancer agents,” Ars Pharmaceutica, vol. 59, no. 3, pp. 121–131,
2018.
[16] M. Bingul, O. Tan, C. Gardner et al., “Synthesis, character-
ization and anti-cancer activity of hydrazide derivatives in-
corporating a quinoline moiety,” Molecules, vol. 21, no. 7,
p. 916, 2016.
[17] M. Zemtsova, A. Zimichev, P. Trakhtenberg, Y. Klimochkin et al.,
“Synthesis and antiviral activity of several quinoline derivatives,”
Pharmaceutical Chemistry Journal, vol. 45, no. 5, 2011.
[18] M. Zemtsova, A. Zimichev, P. Trakhtenberg, R. Belen’kaya,
and E. Boreko, “Synthesis and antiviral activity of 4-quino-
linecarboxylic acid hydrazides,” Pharmaceutical Chemistry
Journal, vol. 42, no. 10, 2008.
1
methoxyquinoline-3-carbaldehyde (5). Figure 5: H NMR
(400 MHz, CDCl3) spectrum of 2-ethoxyquinoline-3-carbal-
dehyde (6). Figure 6:13C NMR (100 MHz, CDCl3) spectrum of
1
2-ethoxyquinoline-3-carbaldehyde (6). Figure 7: H NMR
(400 MHz, DMSO-d6) spectrum of 2-thiocyanatoquinoline-3-
carbaldehyde. Figure 8: 1H NMR (400 MHz, DMSO-d6)
spectrum of 2-chloroquinoline-3-carboxylic acid (8). Figure 9:
13C NMR (100 MHz, DMSO-d6) spectrum of 2-ethox-
yquinoline-3-carbaldehyde (8). Figure 10: 1H NMR (400 MHz,
CDCl3) spectrum of 2-nitro-12H-chromeno[2,3-b]quinolin-
12-one (11). Figure 11: 13C NMR (100 MHz, CDCl3) spectrum
of 2-nitro-12H-chromeno[2,3-b]quinolin-12-one (11). Fig-
ure 12: 1H NMR (400 MHz; CDCl3) spectrum of 2-chloro-8-
methylquinoline-3-carbaldehyde (14). Figure 13: 13C NMR
(100 MHz; CDCl3) spectrum of 2-chloro-8-methylquinoline-
3-carbaldehyde (14). Figure 14: 1H NMR (400 MHz; CDCl3)
spectrum of 8-methyl-2-oxoquinoline-3-carbaldehyde (15).
Figure 15: 13C NMR (100 MHz; CDCl3) spectrum of 8-methyl-
2-oxoquinoline-3-carbaldehyde (15). Figure 16: 1H NMR
spectrum (400 MHz; CDCl3) of (2-methoxy-8-methyl-
quinolin-3-yl)methanol (16). Figure 17: 13C NMR spectrum
(100 MHz; CDCl3) of (2-methoxy-8-methylquinolin-3-yl)
methanol (16). Figure 18: 1H NMR (400 MHz; CDCl3)
spectrum of (2-ethoxy-8-methylquinolin-3-yl)methanol (17).
Figure 19: 13C NMR (100 MHz; CDCl3) spectrum of (2-eth-
References
[1] K. D. +omas, A. V. Adhikari, and N. S. Shetty, “Design,
synthesis and antimicrobial activities of some new quinoline
derivatives carrying 1,2,3-triazole moiety,” European Journal
of Medicinal Chemistry, vol. 45, no. 9, pp. 3803–3810, 2010.
[2] O. Navneetha, K. Deepthi, A. Muralidha Rao, and T. Jyostn,
“A review on chemotherapeutic activities of quinoline,”
IJPCBS, vol. 7, no. 4, pp. 364–372, 2017.
[3] S. Poonam, K. Kamaldeep, C. Amit, S. RranJdh, and
R. Dhawan, “A review on biological activities of quinoline
derivatives,” Journal of Management, Information Technology
and Engineering, vol. 2, no. 1, pp. 1–14, 2016.
[4] M. Emmerson and A. Jnes, “+e quinolones: decades of
development and use,” Journal of Antimicrobial Chemother-
apy, vol. 51, pp. 13–20, 2003.
[5] G. S. Bisacchi, “Origins of the quinolone class of antibacte-
rials: an expanded “discovery story1,” Journal of Medicinal
Chemistry, vol. 58, no. 12, pp. 4874–4882, 2015.
[19] P. Miniyar, M. Barmade, and A. Mahajan, “Synthesis and
biological evaluation of 1-(5-(2-chloroquinolin-3-yl)-3-phe-
nyl-1H-pyrazol1-yl)ethanone derivatives as potential anti-
microbial agents,” Journal of Saudi Chemical Society, vol. 19,
no. 6, pp. 655–660, 2014.
[20] P. G. Mandhane, R. S. Joshi, P. S. Mahajan, M. D. Nikam,
D. R. Nagargoje, and C. H. Gill, “Synthesis, characterization
and antimicrobial screening of substituted quiazolinones
derivatives,” Arabian Journal of Chemistry, vol. 8, no. 4,
pp. 474–479, 2015.
[21] A. Ansari, S. Ahmed, M. Waheed, and A. Juned, “Extraction
and determination of antioxidant activity of Withania som-
nifera Dunal,” European Journal of Experimental Biology,
vol. 3, no. 5, pp. 502–507, 2013.
[22] O. Trott and A. J. Olson, “AutoDock Vina: improving the
speed and accuracy of docking with a new scoring function,
efficient optimization, and multithreading,” Journal of
Computational Chemistry, vol. 31, no. 2, pp. 455–461, 2010.
[23] S. Narramore, C. E. M. Stevenson, A. Maxwell, D. M. Lawson,
and C. W. G. Fishwick, “New insights into the binding mode
of pyridine-3-carboxamide inhibitors of E. coli DNA gyrase,”
[6] P. Sharma, A. Jain, and S. Jain, “Fluoroquinolone antibac-
terials: a review on chemistry, microbiology and therapeutic
prospects,” Acta Poloniae Pharmaceutica-Drug Research,
vol. 66, no. 6, pp. 587–604, 2009.
[7] G. Sarkozy, “Quinolones: a class of antimicrobial agents,”
Veterina´rn´ı Medic´ına, vol. 46, no. 9–10, pp. 257–274, 2001.
[8] N. Riahifard, K. Tavakoli, J. Yamaki, K. Parang, and R. Tiwari,
“Synthesis and evaluation of antimicrobial activity of
[R4W4K]-Levofloxacin and [R4W4K]-Levofloxacin-Q con-
jugates,” Molecules, vol. 22, no. 6, p. 957, 2017.
´
¨
Bioorganic
& Medicinal Chemistry, vol. 27, no. 16,
pp. 3546–3550, 2019.
[24] D. Seeliger and B. L. de Groot, “Ligand docking and binding
site analysis with PyMOL and Autodock/Vina,” Journal of
Computer-Aided Molecular Design, vol. 24, no. 5, pp. 417–422,
2010.
[9] C. Y. Hong, “Discovery of gemifloxacin (Factive, LB20304a): a
quinolone of new a generation,” Il Farmaco, vol. 56, no. 1-2,
pp. 41–44, 2001.